Harvard life sciences spin-out Macrolide secures $22m at launch.
Macrolide Pharmaceuticals has raised $22m in a series A following it being spun out of Harvard University.
The round was backed by life science investors the Novartis Venture Fund, Gurnet Point Capital, Roche Ventures, and SROne. The financing will allow the firm to expand its drug discovery platform into developing a range of novel antibiotics known as macrolides.
Although the technology, which can be used to treat conditions caused by drug resistant pathogens, has been around since the 1940s, it…
